Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-525-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-10-23"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20121023.45.2-525-000"2
lpv:hasSubsequent	lp_eu:2012-10-23-Speech-2-526-0002
lpv:speaker	lp:Inês Cristina Zuber2
lpv:spokenAs	substitute; Delegation for relations with the Mercosur countries (2012-03-05--2014-06-30)3 vice-chair; Delegation for relations with the countries of Central America (2012-03-19--2014-06-30)3 member; Delegation to the Euro-Latin American Parliamentary Assembly (2012-03-12--2014-06-30)3 substitute; CULT (2012-01-19--2014-06-30)3 substitute; ITRE (2012-01-19--2014-06-30)3 vice-chair; EMPL (2012-01-25--2014-06-30)3 unknown; Partido Comunista Português (2012-01-18--2014-06-30)3 member; FEMM (2012-01-19--2014-06-30)3 member; EUL/NGL (2012-01-18--2014-06-30)3
lpv:translated text	"This report approves the mobilisation of the EGF in the amount of EUR 4 325 854 in order to in the labour market of 987 workers made redundant by AstraZeneca in Sweden, in the pharmaceutical sector, due to what the Commission regards as . Unlike various Asian countries which, during the recession, have increased their investment in R&D, the EU’s policy, which is fixated with tackling the deficits, is to restrict public support for R&D, an approach that could last for years, with inevitable consequences on employment rates and medical research. We continue to disagree with the creation of a Fund that also serves to legitimise the policy of redundancies and unemployment, without attacking its real causes."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph